LXRP: Bioscience Technology Disruptor In Burgeoning Marijuana Sector
February 16, 2017

Penny Stock Profile ….


Lexaria Bioscience Corp.

For complete profile, .

"Lexaria Bioscience Corp., a bioscience technology disruptor in the burgeoning marijuana sector."

Quote & News


LXRP Profile

Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) is a bioscience technology disruptor for edible cannabinoids. The Company’s technology masks the bitter taste of marijuana, provides faster acting delivery (15 -20 min for THC vs 60 – 120 minutes for industry norms) and has increased potency with an overall lower dosage. With its presence in the Canadian as well as U.S. market, Lexaria Bioscience is uniquely positioned to benefit from the relaxation in marijuana laws in both Countries.

Canada has recently taken important steps to deregulate marijuana use in the country. These steps are expected to result in a substantial increase in demand for marijuana products for medicinal and recreational use. Late last year, a marijuana task force completed its report providing guidelines for legalizing cannabis use. The report is currently under consideration.

According to industry experts, the cannabis market in Canada is expected to grow to $4.5 billion by 2021. Similarly, the United States, which is another major market for Lexaria Bioscience has taken even bolder steps towards legalizing marijuana use. On the U.S. election day in November, seven states legalized the use of cannabis in various forms. The prediction for the marijuana market in the United States suggest that the industry may be worth more than $50 billion by 2026.

These developments are highly important for Lexaria Bioscience which is looking to gain a leadership position with its proprietary technology aimed at the marijuana market. In line with regulators taking major steps towards boosting the cannabis industry, Lexaria Bioscience is also working towards cementing its position in the fast growing and newly legal market.

The Company has been very busy of late moving forward with their corporate vision.  The company recently signed a master collaborative research agreement with the National Research Council of Canada. The new deal is important as it will help the company in increasing the demand for its patented flavour masking and nutrient delivery enhancement technology.

Lexaria Bioscience is also working towards developing new products. It recently announced the successful development and initial trial of the industry's first zero-sugar cannabinoid / pterostilbene edible tablet. The company collaborated with NeutriSci International Inc. on the product with the process using Lexaria Bioscience’s CBD conjugation technology. The trials showed that the tablets were able to provide faster and longer lasting effects with smaller dosage than competing products.

Lexaria’s technology is already patented in the United States, and is under process in Canada and 41 other countries including Japan, China and India. It received its U.S. patent nod in October and filed for international patents in December.

Over the course of the past 12 months, various ventures such as patent wins and product developments have helped the company’s shares post an over 530% gain. Shares are up close to 81% on a year-to-date basis alone.

Investors looking for a Company with a focus on the burgeoning marijuana sector, but not in the business of growing the product may want to consider Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) for their stock portfolio.  The Company provides investors with product diversity, technological patents, growing revenues and strong share price growth under one umbrella.

As always, more information on the Company can be found on, or by clicking here.


Corporate Information

  • Exchange: OTCQB
  • Market Cap: 29.44 Million
  • Outstanding Shares: 55.5 Million
  • Price: $0.53
  • 52 Week Low / High: $0.08 / $0.699
  • Information As Of February 16, 2017



  Forward Looking Statements

This report includes forward-looking statements that reflect Lexaria Bioscience Corp. current expectations about its future results, performance, prospects and opportunities. Lexaria Bioscience Corp. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Lexaria Bioscience Corp.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.

Disclaimer feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Lexaria Bioscience Corp. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.

© 1999-2017 All rights reserved. is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), will disclose in it's disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the web site. has been compensated two thousand five hundred dollars from a third-party, Frontier Consulting, Ltd. for its efforts in presenting the LXRG profile on its web site and distributing it to its database of subscribers as well as other services. may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. As of the profile date, no shares have been sold or held by Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as “expects’”, “will,” “anticipates,” “estimates, “believes,” or that by statements indicating certain actions “may,” “could,” or “might” occur.


We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission (SEC) at: and/or the National Association of Securities Dealers (NASD) at: Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.

This message was sent from Media, Inc., P.O. Box 1181 Stn. B, Mississauga ON, L4Y3W5 Canada


Related Post

Blue Horseshoe Stocks: WFM Followup, ZSAN & More

Vanguard’s Best and Worst Funds for 2017